Biodexa Pharmaceuticals (BDRX) received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis. The news follows Biodexa reporting positive 12-month data from a phase 2 clinical trial in July 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biodexa Pharmaceuticals Receives FDA Fast Track for eRapa in FAP Treatment
- Biodexa Pharmaceuticals Enhances Leadership with New Chief Medical Officer
- Biodexa Pharmaceuticals appoints Shangold as Chief Medical Officer
- Biodexa Pharmaceuticals files to sell 35.875M ADS for holders
- Biodexa Pharmaceuticals Secures Flexible $35 Million Funding Agreement